Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 3, 2016In a keynote address on patient-centric leadership at the eyeforpharma Philadelphia Summit, CSL Chief Executive Officer and Managing Director Paul Perreault called on fellow industry leaders to do much more to connect with and learn from patients.
03 May 2016 A successful Pharma of the future requires a much different, authentic form of patient engagement Patient-centric leadership is fully embedded across CSL’s organization since its...
-
Apr 28, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Apr 25, 2016CSL Behring today commemorated 100 years of developing and delivering innovative therapies to treat people with life-threatening medical conditions and help them live full lives.
25 Apr 2016 Locally, Company donates 100 trees to Valley Forge National Historical Park to mark centennial anniversary Shipment is a part of CSL Behring’s three year promise to provide more than...
-
Apr 25, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Apr 13, 2016“Treatment for All is the Vision for All” is the World Federation of Hemophilia’s (WFH) global message for World Hemophilia Day this year (April 17, 2016). Demonstrating that purpose, the WFH and global biotherapeutics leader CSL Behring announced today that CSL Behring has shipped more than 1.5 million international units (IUs) of its specialty biotherapeutics to treat hemophilia A and/or von Willebrand Disease to the WFH Global Alliance for Progress (GAP) Program and other WFH programs.
13 Apr 2016 More than 1.5 million international units (IUs) of treatments for Hemophilia A and/or von Willebrand Disease shipped in advance of World Hemophilia Day Shipment is a part of CSL Behring’
-
Apr 5, 2016CSL Behring announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) supports maintaining the orphan designation for IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein]. IDELVION® is CSL Behring’s novel, long-acting recombinant albumin fusion protein for treating hemophilia.
05 Apr 2016 CSL Behring announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) supports maintaining the orphan designation for IDELVION®...
-
Mar 21, 2016CSL Behring announced today that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting recombinant albumin fusion protein for treating hemophilia B, is now available nationwide.
21 Mar 2016 In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00 IDELVION, CSL...
-
Mar 15, 2016A new webinar series addresses the unique needs of young adults living with Primary Immunodeficiency at a critical time when they are transitioning from teen to adulthood and taking responsibility for their own care.
15 Mar 2016 In honor of the upcoming World Primary Immunodeficiencies (PI) Week, CSL Behring is proud to sponsor Immune Deficiency Foundation’s new PI Voices, Young Adult Webinar Series. The...
-
Mar 15, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 9, 2016CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy ObjectivesPatients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them with the announcement of the latest round of LEAD Grant awards. CSL Behring established the LEAD grant program in 2008 to help support the important advocacy work of patient groups in tackling complex legislative and public policy issues.
09 Mar 2016 Patients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them with the announcement of the latest...